drugset / Trial / NCT05553470
Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to determine the effect of hepatic impairment on the pharmacokinetics (PK) of miricorilant following a single oral dose by comparing participants with normal hepatic function with participants with moderate hepatic impairment with or without nonalcoholic steatohepatitis (NASH).
Timeline
- Start
- 2022-03-03
- Primary completion
- 2024-09-13
- Completion
- 2024-09-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Miricorilant | Small molecule | 600 mg | Oral |